Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,002 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Treatment Gel Clear all
Completed Not applicable Interventional

Perf-Fix Study for Chronic Tympanic Membrane Repair

NCT06083181
View directory record Official record
Conditions
Tympanic Membrane Perforation
Interventions
Perf-Fix Otologic Gel Patch
Device
Lead sponsor
Tympanogen
Industry
Eligibility
5 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Louisville, Kentucky • Mandeville, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Not applicable Interventional Results available

The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL

NCT03873272
View directory record Official record
Conditions
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions
Cryotherapy, Compression Therapy, Loose glove/sock
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face

NCT03393494
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene and Benzoyl Peroxide Topical Gel, Epiduo Topical Product, Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Multicenter, Open-Label Retreatment Study of the Safety and Effectiveness of PN40082 for Lip Augmentation

NCT04029519
View directory record Official record
Conditions
Lip Augmentation
Interventions
PN40082
Device
Lead sponsor
Prollenium Medical Technologies Inc.
Industry
Eligibility
21 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Encinitas, California • Miami, Florida • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 1 Interventional

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

NCT01836367
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate 0.015%
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition

NCT03712137
View directory record Official record
Conditions
Jawline Definition
Interventions
VOLUX XC, No-treatment control
Device · Other
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Rosa, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 25, 2026, 6:03 PM EDT
Not listed No phase listed Observational

(ACTH) for the Treatment of Sarcoid Uveitis

NCT03473964
View directory record Official record
Conditions
Sarcoid Uveitis
Interventions
H.P. Acthar gel
Drug
Lead sponsor
John Huang, MD
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Hamden, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Prospective Evaluation of the Filler for Jaw Contouring

NCT06694857
View directory record Official record
Conditions
Dermal Fillers
Interventions
HA filler
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products

NCT01313728
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone plus Tretinoin Gel, Tretinoin Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

NCT01501799
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel)
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Fremont, California • Miami, Florida • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 25, 2026, 6:03 PM EDT
Recruiting Phase 3 Interventional

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

NCT04423211
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
Radiation · Drug · Procedure + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
341
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Vitamin D Insufficiency

NCT00933244
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
High Dose Vitamin D3, Low Dose Vitamin D3, Placebo
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 75 Years · Female only
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream

NCT03727074
View directory record Official record
Conditions
Actinic Keratosis (AK)
Interventions
5-FU Cream, Efudex®, Vehicle
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cerritos, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 1 Interventional

Pulse ACTH vs. MP for MS

NCT01049451
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTH, Methylprednisolone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

NCT03988530
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine, Placebo Nasal Gel
Drug · Other
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
55 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 25, 2026, 6:03 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers

NCT00316537
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
ATG002 (study drug)
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2007 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy

NCT00388297
View directory record Official record
Conditions
Subclinical Hypothyroidism, Hypothyroxinemia, Pregnancy
Interventions
Levothyroxine, Placebo for Levothyroxine
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
1,203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 25, 2026, 6:03 PM EDT
Suspended Phase 4 Interventional

PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)

NCT07636161
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes (T2DM)
Interventions
Eroxon®, tadalafil
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

RHA® Redensity With New Anesthetic Agent - Perioral Rhytids

NCT04069585
View directory record Official record
Conditions
Aging, Pain
Interventions
RHA® Redensity with new anesthetic agent, RHA® Redensity with lidocaine
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Beverly Hills, California • Coral Gables, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 25, 2026, 6:03 PM EDT
Not listed Not applicable Interventional

COPD Remote Patient Monitoring Through Connected Devices

NCT05271474
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
ANNE ONE Platform
Device
Lead sponsor
Innovation Hub Enterprises
Industry
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 3 Interventional Results available

Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts

NCT03532776
View directory record Official record
Conditions
External Anogenital Warts
Interventions
Podofilox Gel 0.5%, Condylox Topical Gel 0.5%, Placebo Gel
Drug
Lead sponsor
Dermax SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

NCT00419419
View directory record Official record
Conditions
Raynaud's Disease, Scleroderma, Autoimmune Diseases
Interventions
Topical AmphiMatrix with nitroglycerin (MQX-503)
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
6
States / cities
Stanford, California • Farmington, Connecticut • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 25, 2026, 6:03 PM EDT
Recruiting No phase listed Observational

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

NCT05874921
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Interventions
Jelmyto (mitomycin) for pyelocalyceal solution
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
22
States / cities
Santa Monica, California • Gainesville, Florida • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 6:03 PM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

NCT02176356
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
Interventions
onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC
Biological · Drug · Device
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 25, 2026, 6:03 PM EDT